said David Ricks.

A large majority of patients completing this 6-month trial opted to take part in a long-term extension study. Detailed data from the RA-BEACON study will be provided at scientific meetings in 2015. Lilly and Incyte are analyzing the safety and efficacy of baricitinib in an extensive Phase 3 program with a total enrollment of over 3,000 people who have rheumatoid arthritis.. Arthritis medication baricitinib meets major endpoint in Phase 3 RA-BEACON study Eli Lilly and Organization and Incyte Corporation today announce that the Phase 3 RA-BEACON research of the investigational medicine baricitinib met its principal endpoint of improved ACR20 response in comparison to placebo after 12 weeks of treatment.Individuals with resistant hypertension are nearly 50 % more likely to experience a cardiovascular event than hypertensive sufferers without resistant hypertension, and the incidence of resistant hypertension can be expected to boost, according to background information in the article. Recent studies show that obstructive sleep apnea [OSA] may donate to poor control of blood circulation pressure and that a very high %age of resistant hypertension patients have OSA. Continuous positive airway pressure may be the treatment of choice for severe or symptomatic OSA. A meta-analysis shows that CPAP treatment decreases blood pressure levels to a clinically meaningful level, but whether this positive impact is even more pronounced in patients with resistant hypertension is definitely unclear because studies upon this issue are scarce and predicated on single-center techniques.

Comments are closed.